Rebecca Taylor
About Rebecca Taylor
Rebecca Taylor serves as the Director of Intellectual Property at CytomX Therapeutics, where she has worked since 2020. With a strong background in biological sciences and over two decades of experience in intellectual property management, she has advanced through various roles within the company.
Work at CytomX Therapeutics
Rebecca Taylor has been employed at CytomX Therapeutics since 2011, starting as an IP Consultant. She held this position until 2016, after which she became Associate Director of Intellectual Property, serving in that role until 2020. In 2020, she was promoted to Director of Intellectual Property, a position she continues to hold. Her tenure at CytomX Therapeutics spans over a decade, during which she has contributed significantly to the company's intellectual property strategy and management.
Education and Expertise
Rebecca Taylor holds a BSc with Honors in Applied Biology (Biochemistry) from the University of Central Lancashire, which she completed from 1987 to 1990. She furthered her education at Stanford University, where she earned an MSc in Biological Sciences from 1994 to 1996. Her academic background provides a strong foundation in biological sciences, complementing her expertise in intellectual property management.
Background
Rebecca Taylor has over two decades of experience in the field of intellectual property management and consulting. She began her career as a Senior Research Associate II at Geron Corporation from 1996 to 2002. Following this, she worked as an IP Consultant at Signature Therapeutics from 2009 to 2015. Her extensive experience in both research and intellectual property has equipped her with a comprehensive understanding of the biotech industry.
Achievements
Rebecca Taylor has been a Registered Patent Agent since January 2003, which underscores her qualifications in the field of intellectual property. Her progression from IP Consultant to Director of Intellectual Property at CytomX Therapeutics reflects her expertise and commitment to the management of intellectual property within the biotechnology sector.